Ọ bụrụ na ị na-eme nchọpụta na ọgwụ ndị dị na levothyroxine na ọgwụ frothyronine iji mesoo hypothyroidism gị, ị nwere ike ịnụ banyere nchọpụta US Food and Drug Administration (FDA) n'ime Mylan. Mylan bụ onye na-eme ọgwụ ọjọọ nke atọ n'ụwa, na-emepụta levothyroxine na horsethyronine, ụdị usoro ọgwụ nke Cytomel . Ma ọgwụ ọjọọ bụ thyroid hormone nnọchi ọgwụ iji dozie hypothyroidism.
N'oge okpomọkụ nke afọ 2009, FDA meghere nchọpụta, ma n'ime izu ole na ole, a nyochachara nchọpụta ahụ, ọ dịghịkwa ihe gosiri na e metụrụ àgwà ọgwụ ọjọọ ndị Mylan, gụnyere levothyroxine.
Nke a bụ ozi ị chọrọ ịmara iji mee mkpebi nyocha banyere ọgwụ ndị a.
Azụ
N'afọ 2009, Mylan bụ West Virginia bụ isiokwu nke nchọpụta gọọmenti etiti na nsogbu mmepụta ihe na osisi ha. Akwụkwọ akụkọ Pittsburgh Post Gazette mebiri akụkọ banyere ndị ọrụ na Mylan's West Virginia osisi, bụ ndị dị, dịka akwụkwọ ederede nke Post-Gazette nweta , "na-agbanyekarị ịdọ aka ná ntị na kọmputa site na ịdọ aka ná ntị banyere nsogbu ndị nwere nsogbu na ọgwụ ndị ha na-emepụta."
N'oge ahụ, FDA kwupụtara na Mylan na-etinye aka n'ịghaghasị ozi ma gbanwee ngwaahịa, ikekwe ruo ogologo oge dịka afọ abụọ ma ọ bụ karịa. Mgbe FDA meghere nchọpụta na Mylan, ụlọ ọrụ ahụ kwupụtara nkwupụta na-egosi na nchọpụta FDA bụ ihe omume.
FDA, weere nzọụkwụ pụrụ iche nke ịnye nkwupụta iji chegharịa ma kwụsị ọrụ mgbalị Mylan iji kọwaa oke nyocha ahụ.
N'oge a malitere nyocha ahụ, Pittsburgh Post-Gazette nyere nkọwa zuru oke nke ọnọdụ Mylan, tinyere isiokwu ndị na-esonụ:
- Ndị ọrụ m na-ekpochapụ njikwa njikwa ọgwụ, Ozi nchịkọta akụkọ zuru ezu na-egosi na ị na-eleghara usoro nchekwa anya - July 26, 2009
- Mylan's 'red screen' usoro iheomume - July 26, 2009
- FDA na-achọ ihe omume Mylan, A na-ekwu na imebi ihe nchịkwa n'ime akụkọ nke ụlọ - July 28, 2009
- "FDA kwụsịrị nkwupụta Mylan" - July 28, 2009
Mgbe izu ole na ole nke Mylan na-ere ahịa ahịa dara, Mylan na FDA weere okwu agha ọha na eze na mgbasa ozi. Mylan kwara ndị nta akụkọ Pittsburgh Post Gazette bụ ndị mebiri akụkọ maka nkwulu.
FDA mechara kpochapụ Mylan, na - eme ọkwa na August 13, 2009. Dị ka FDA si kwuo, Mylan eduziri nyocha zuru oke, onye na-ekwuchitere ụlọ ọrụ, na FDA mechiri nchọpụta ahụ.
Akpadoro ikpe Mylan megide akwụkwọ akụkọ ahụ na 2012, Mylan na Post-Gazette wepụtara otu nkwupụta nke kwuru, n'otu akụkụ:
E kpebiri ikpe ahụ gbasara afọ ojuju nke abụọ. The Post-Gazette ahụghị ma ọ bu n'obi ịkọ na Mylan arụpụtara ma ọ bụ kesaa ụdị ọgwụ ọjọọ ọ bụla.
Okwu si
N'akụkụ nke ọnọdụ a maka ndị ọrịa na-agwọ ọrịa bụ na ọ dịghị ihe akaebe na-egosi na ụdị ọgwụ ndị Mylan mepụtara, gụnyere ọgwụ ndị levothyroxine na ọgwụthythyine nke ọtụtụ ndị nwere hypothyroidism mere, emetụta ya n'ụzọ ọ bụla.
N'otu oge ahụ, ndị nwere hypothyroidism na-ewere ọgwụ thyroid hormone na-agbanwe ọgwụ levothyroxine mkpa ịmara na ọtụtụ ndị dọkịta anaghị eme atụmatụ na thyroid ọrịa na-ewere ihe ọ bụla ọnụọgụ levothyroxine si ọ bụla emeputa. Ihe kpatara ya bụ na ọgwụ niile levothyroxine, tinyere ọgwụ ndị na-ahazi na ọgwụ aha, na-akwado iwu ka ha nwee ike ịdị iche na pasent 95 ruo pasent 105 nke usoro ọgwụgwọ ahụ. Mgbe ị na-ewere levothyroxine, ọnye nwere ike ịpụta site na onye ọ bụla na-emepụta ihe, nke pụtara na nyocha ọ bụla nke usoro ọgwụ kwuru nwere ike ịda n'ebe ọ bụla n'ime nsogbu ahụ.
Ọbụna obere mgbanwe dị iche iche nwere ike igbochi ịdị irè nke ọgwụ gị na-agbanwe ọgwụgwọ gịroid.
Stable thyroid hormone replace is also especially important for thyroid cancer survivors, onye nwere ike na-achọ iso kwusi thyroid na-akpali akpali hormone (TSH) etoju dị ka akụkụ nke ọgwụgwọ ha, na iji gbochie nlọghachi nke ọrịa cancer thyroid.
Ọ bụrụ na ị na-eji levothyroxine na-ewepụta ọnụọgụ ọnụọgụ site n'aka onye ọ bụla mepụtara, ọ ga-enye aka ịkọwa ọnọdụ gị kpọmkwem na onye nlekọta ahụike gị, iji chọpụta ma ọ bụrụ na ọgwụ aha ga-abụ nhọrọ ka mma maka ọgwụgwọ gị.